Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. is an advanced clinical stage drug development company with a platform technology that addresses multibillion dollar markets in the treatment of cancer, inflammatory and other diseases. The completed its Phase 2/3 trials for psoriasis and is in Phase 2 trials for liver cancer. Study design for a Phase 3 trial in rheumatoid arthritis has been completed. Can-Fite has been granted orphan drug designation by the U.S. FDA for its liver cancer drug, which is approved for compassionate use by Israel's Ministry of Health. The company's drug candidates have an excellent safety profile with experience in over 1,200 patients.